A modern approach to the diagnosis and evaluation of regression after neoadjuvant therapy in breast cancer patients
https://doi.org/10.18027/2224-5057-2017-1-38-41
Abstract
Complete pathological tumor response is now considered the main criterion of effectiveness of neoadjuvant therapy and has great prognostic value. The paper describes the modern approach to the definition of residual tumor in breast cancer patients after
neoadjuvant chemotherapy, the criteria of a full morphological regression according to the latest clinical guidelines.
neoadjuvant chemotherapy, the criteria of a full morphological regression according to the latest clinical guidelines.
About the Authors
L. V. MOSKVINA
Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation, Clinical Hospital One
Russian Federation
MD, PhD, assistant of pathology department, pathologis
Russian Federation
MD, PhD, assistant of pathology department, pathologis
Y. Y. ANDREEVA
Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation
Russian Federation
MD, PhD, DSc, professor at the Department of Pathology
Russian Federation
MD, PhD, DSc, professor at the Department of Pathology
M. E. ILATOVSKAIA
Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation
Russian Federation
MB, PhD, assistant of pathology department
Russian Federation
MB, PhD, assistant of pathology department
A. E. MATSIONIS
GBU RO “Pathoanatomical Bureau”
Russian Federation
MD, PhD, DSc, academician of RANS, head of the laboratory of
immunomorphology,
Russian Federation
MD, PhD, DSc, academician of RANS, head of the laboratory of
immunomorphology,
G. A. FRANK
Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation
Russian Federation
MD, PhD, DSc, academician of RAS, head of the Department of Pathology
Russian Federation
MD, PhD, DSc, academician of RAS, head of the Department of Pathology
L. E. ZAVALISHINA
Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation
Russian Federation
MD, PhD, DSc, professor at the Department of Pathology
Russian Federation
MD, PhD, DSc, professor at the Department of Pathology
Y. L. PODBEREZINA
Clinical Hospital One
Russian Federation
MD, PhD, head of the division of oncology, plastic and reconstructive Surgery
Russian Federation
MD, PhD, head of the division of oncology, plastic and reconstructive Surgery
References
1. Колядина И. В., Поддубная И. В. Современные возможности терапии HER2-положительного рака молочной железы (по материалам клинических исследований). Современная онкология. 2014; № 4: 10–20 I. V. Kolyadina, I. V. Poddubnaya. Modern possibilities of HER2 positive breast cancer treatment (based on clinical trials). Sovremennaya oncol. 2014; № 4: 10–20.
2. Gianni L., Eiermann W., Semiglazov V., Lluch A., Tjulandin S., Zambetti M., Moliterni A. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 2014; 15(6): 640–7.
3. NCCN Guidelines Version 1.2016. Invasive Breast Cancer.
4. Bossuyt V., Provenzano E., Symmans W. F. et al. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol. 2015; 26(7): 1280–91.
5. von Minckwitz G., Untch M., Blohmer J. U. et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30: 1796–804.
6. Lakhani S. R., Ellis I. O., Schnitt S. J., Tan P. H., van de Vijver M. J. (Ed.): WHO Classification of Tumours of the Breast. IARC: Lyon 2012.
7. E. Senkus et al. Primary Breast Cancer: ESMO Clinical Practice Guidelines. Ann Oncol (2015) 26 (suppl 5): v8-v30. 8. Symmans W. F., Peintinger F., Hatzis C. et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007; 25(28): 4414–22.
8. Penault-Llorca F., Radosevic-Robin N. Nature reviews, clinical oncology 2016.
9. Андреева Ю. Ю., Москвина Л. В., Березина Т. А., Подберезина Ю. Л., Локтев С. С., Франк Г. А. Методика исследования операционного материала при раке молочной железы после неоадъювантной терапии для оценки остаточной опухолевой нагрузки (по системе RCB). Архив патологии, 2016. – N2. – С. 41–46. Andreeva Y.Y., Moskvina L.V., Berezina T.A., Podberezina Y.L., Loktev S.S., Frank G.A. Procedure for intraoperative material examination in breast cancer after neoadjuvant therapy to estimate residual cancer burden using the RCB system. Arkh Patol. 2016 Mar-Apr;78(2):41–46.
10. Андреева Ю. Ю. и др. Рак молочной железы. Практическое руководство для врачей. Под ред. Г. А. Франка, Л. Э. Завалишиной, К. М. Пожарисского. М.: Практическая медицина, 2014. Andreeva Iu.Iu. i dr. Rak molochnoi zhelezy. Prakticheskoe rukovodstvo dlia vrachei. Pod red. G. A. Franka, L. E. Zavalishinoi, K. M. Pozharisskogo. M.: Prakticheskaia meditsina, 2014.
11. Sahoo S., Dabbs D. J., Bhargava R. Pathology of Neoadjuvant Therapeutic Response of Breast Carcinoma. Breast pathology. Philadelphia: Elsevier, 2012; p. 519–33.
Review
For citations:
MOSKVINA L.V., ANDREEVA Y.Y., ILATOVSKAIA M.E., MATSIONIS A.E., FRANK G.A., ZAVALISHINA L.E., PODBEREZINA Y.L. A modern approach to the diagnosis and evaluation of regression after neoadjuvant therapy in breast cancer patients. Malignant tumours. 2017;(1):38-41. (In Russ.) https://doi.org/10.18027/2224-5057-2017-1-38-41
Views:
1042
Email this article 